NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Telomir Pharmaceuticals' Telomir-1 IND-Enabling Safety Results
TL;DR
Telomir Pharmaceuticals' Telomir-1 shows no adverse toxicities in preclinical studies, positioning it as a promising candidate for investors seeking early-stage biotech opportunities.
Telomir-1 demonstrated consistent systemic exposure and predictable pharmacokinetics with no dose-limiting toxicities across cardiovascular, respiratory, and repeat-dose evaluations in rodent and non-rodent models.
Telomir-1's safety profile advances potential treatments targeting cancer and aging mechanisms, offering hope for improved health outcomes and quality of life.
Telomir Pharmaceuticals' Telomir-1 successfully passed comprehensive toxicology studies without concerning safety signals, moving closer to human trials for epigenetic therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals announced favorable results from IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1, reporting no treatment-related adverse or dose-limiting toxicities across multiple evaluations.
The studies included cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models, with Telomir-1 showing no concerning cardiac or respiratory safety signals and no phototoxic potential.
Telomir-1 was well tolerated with no treatment-related adverse or dose-limiting toxicities, demonstrated consistent systemic exposure and predictable pharmacokinetics following oral administration, and showed only limited, reversible, and non-adverse findings in repeated-dose studies.
Telomir-1 (also called Zn-Telomir) is a small-molecule therapeutic designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative disease, with demonstrated activity in modulating DNA and histone methylation, restoring redox balance, and normalizing cellular function.
The favorable safety results support continued advancement toward first-in-human clinical development, pending completion of final quality assurance review and applicable regulatory pathways.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company, with Telomir-1 being its lead therapeutic candidate currently undergoing IND-enabling studies.
The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO.
The full press release can be viewed at https://ibn.fm/Gaxtl.
InvestorWire published this announcement, which is a specialized communications platform providing wire-grade press release syndication, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
Curated from InvestorBrandNetwork (IBN)
